Document Detail

Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy.
MedLine Citation:
PMID:  25355720     Owner:  NLM     Status:  Publisher    
BACKGROUND: The Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2013 to provide a set of specific recommendations regarding patient-reported outcomes (PROs) reporting in randomized clinical trials (RCTs). There is limited data regarding how well current publications of oncology RCTs report PROs if assessed using these guidelines.
DESIGN: All phase III medical oncology RCTs published between 2007 and 2011 were reviewed according to the 2013 PROs CONSORT recommendations and a 11-point PROs reporting quality score (PRORQS) was defined based on the criteria.
RESULTS: The majority of trials did not report on PROs at all (201 of 325; 62%). Of the remaining 124 trials, the mean PRORQS score was 5.0 on an 11 points scale. The items related to methods of PROs collection and analysis were poorly reported (Description of the prespecified PRO hypothesis : 26% of RCTs ; methods for PRO data collection (paper, telephone, electronic, other) : 16% ; statistical approaches for managing missing data : 37%). The only factor significantly associated with improved PROs reporting was where PROs reporting was the subject of a dedicated secondary manuscript, as was the case in 36 of the 124 (29%) of RCTs.
CONCLUSION: Despite their clinical relevance, our findings show that some aspects of PROs reporting may greatly be improved, especially critical methodological aspects of PROs collection and analysis. The exceptions were where PROs were described in PROs-specific secondary publication. Use of the 2013 PROs CONSORT extensions should be encouraged and their effects on PROs reporting subsequently reassessed.
O Bylicki; H K Gan; F Joly; D Maillet; B You; J Péron
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-10-29
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  -     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2014 Oct 
Date Detail:
Created Date:  2014-10-30     Completed Date:  -     Revised Date:  2014-10-31    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemoth...
Next Document:  Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive meta...